$148.93
0.13% yesterday
NYSE, Aug 11, 10:00 pm CET

Charles River Laboratories International, Inc. Stock price

$148.93
-10.47 6.57% 1M
-5.97 3.85% 6M
-35.67 19.32% YTD
-45.38 23.35% 1Y
-77.54 34.24% 3Y
-61.31 29.16% 5Y
+73.59 97.68% 10Y
+97.60 190.14% 20Y
NYSE, Closing price Mon, Aug 11 2025
+0.19 0.13%

Key metrics

Basic
Market capitalization
$7.3b
Enterprise Value
$9.5b
Net debt
$2.2b
Cash
$182.9m
Shares outstanding
49.2m
Valuation (TTM | estimate)
P/E
negative | 15.3
P/S
1.8 | 1.9
EV/Sales
2.4 | 2.4
EV/FCF
16.4
P/B
2.2
Financial Health
Equity Ratio
46.0%
Return on Equity
0.3%
ROCE
7.2%
ROIC
24.8%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$4.0b | $3.9b
EBITDA
$673.4m | $983.2m
EBIT
$469.1m | $742.8m
Net Income
$-69.2m | $477.1m
Free Cash Flow
$578.5m
Growth (TTM | estimate)
Revenue
-1.2% | -2.8%
EBITDA
-11.8% | 42.6%
EBIT
-25.6% | 34.9%
Net Income
-116.0% | 4,532.4%
Free Cash Flow
18.8%
Margin (TTM | estimate)
Gross
35.0%
EBITDA
16.7% | 25.0%
EBIT
11.6%
Net
-1.7% | 12.1%
Free Cash Flow
14.4%
More
EPS
$-1.4
FCF per Share
$11.8
Short interest
5.4%
Employees
19k
Rev per Employee
$210.0k
Show more

Is Charles River Laboratories International, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Charles River Laboratories International, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Charles River Laboratories International, Inc. forecast:

8x Buy
35%
14x Hold
61%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Charles River Laboratories International, Inc. forecast:

Buy
35%
Hold
61%
Sell
4%

Financial data from Charles River Laboratories International, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,029 4,029
1% 1%
100%
- Direct Costs 2,618 2,618
0% 0%
65%
1,411 1,411
4% 4%
35%
- Selling and Administrative Expenses 738 738
5% 5%
18%
- Research and Development Expense - -
-
-
673 673
12% 12%
17%
- Depreciation and Amortization 204 204
53% 53%
5%
EBIT (Operating Income) EBIT 469 469
26% 26%
12%
Net Profit -69 -69
116% 116%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Charles River Laboratories International, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Charles River Laboratories International, Inc. Stock News

Positive
The Motley Fool
5 days ago
Charles River (CRL) Q2 EPS Jumps 11%
Neutral
Seeking Alpha
5 days ago
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
Negative
Seeking Alpha
5 days ago
Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expect...
More Charles River Laboratories International, Inc. News

Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Head office United States
CEO James Foster
Employees 19,400
Founded 1947
Website www.criver.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today